Literature DB >> 16446447

Interaction of MEQ protein and C-terminal-binding protein is critical for induction of lymphomas by Marek's disease virus.

Andrew C Brown1, Susan J Baigent, Lorraine P Smith, Jason P Chattoo, Lawrence J Petherbridge, Pippa Hawes, Martin J Allday, Venugopal Nair.   

Abstract

Marek's disease virus (MDV) is an oncogenic herpesvirus that induces fatal T cell lymphomas in chickens. With more than 20 billion doses of vaccine used annually, vaccination constitutes the cornerstone of Marek's disease control. Despite the success of vaccination, evolution of virulence among MDV strains continues to threaten the effectiveness of the current Marek's disease vaccines. MDV-encoded protein MEQ (MDV EcoRI Q) probably acts as a transcription factor and is considered to be the major MDV oncoprotein. MEQ sequence shows a Pro-Leu-Asp-Leu-Ser (PLDLS) motif known to bind C-terminal-binding protein (CtBP), a highly conserved cellular transcriptional corepressor with roles in the regulation of development, proliferation, and apoptosis. Here we show that MEQ can physically and functionally interact with CtBP through this motif and that this interaction is critical for oncogenesis because mutations in the CtBP-interaction domain completely abolished oncogenicity. This direct role for MEQ-CtBP interaction in MDV oncogenicity highlights the convergent evolution of molecular mechanisms of neoplastic transformation by herpesviruses because Epstein-Barr virus oncoproteins EBNA 3A and 3C also interact with CtBP. We also demonstrate that the nononcogenic MDV generated by mutagenesis of the CtBP-interaction domain of MEQ has the potential to be an improved vaccine against virulent MDV infection. Engineering MDV with precisely defined attenuating mutations, therefore, represents an effective strategy for generating new vaccines against this major poultry disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16446447      PMCID: PMC1413633          DOI: 10.1073/pnas.0507595103

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  25 in total

1.  Pathogenesis of Marek's disease virus infection.

Authors:  B W Calnek
Journal:  Curr Top Microbiol Immunol       Date:  2001       Impact factor: 4.291

2.  Physical and functional interactions between the corepressor CtBP and the Epstein-Barr virus nuclear antigen EBNA3C.

Authors:  R Touitou; M Hickabottom; G Parker; T Crook; M J Allday
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

3.  The genome of a very virulent Marek's disease virus.

Authors:  E R Tulman; C L Afonso; Z Lu; L Zsak; D L Rock; G F Kutish
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

4.  Absolute quantitation of Marek's disease virus genome copy number in chicken feather and lymphocyte samples using real-time PCR.

Authors:  Susan J Baigent; Lawrence J Petherbridge; Ken Howes; Lorraine P Smith; Richard J W Currie; Venugopal K Nair
Journal:  J Virol Methods       Date:  2005-01       Impact factor: 2.014

5.  The corepressor CtBP interacts with Evi-1 to repress transforming growth factor beta signaling.

Authors:  K Izutsu; M Kurokawa; Y Imai; K Maki; K Mitani; H Hirai
Journal:  Blood       Date:  2001-05-01       Impact factor: 22.113

6.  Markerless gene replacement in Escherichia coli stimulated by a double-strand break in the chromosome.

Authors:  G Pósfai; V Kolisnychenko; Z Bereczki; F R Blattner
Journal:  Nucleic Acids Res       Date:  1999-11-15       Impact factor: 16.971

Review 7.  Historical background.

Authors:  M A Epstein
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-04-29       Impact factor: 6.237

Review 8.  Classification of Marek's disease viruses according to pathotype: philosophy and methodology.

Authors:  R L Witter; B W Calnek; C Buscaglia; I M Gimeno; K A Schat
Journal:  Avian Pathol       Date:  2005-04       Impact factor: 3.378

9.  Epstein-Barr virus nuclear protein 3A domains essential for growth of lymphoblasts: transcriptional regulation through RBP-Jkappa/CBF1 is critical.

Authors:  Seiji Maruo; Eric Johannsen; Diego Illanes; Andrew Cooper; Bo Zhao; Elliott Kieff
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

Review 10.  CtBP, an unconventional transcriptional corepressor in development and oncogenesis.

Authors:  G Chinnadurai
Journal:  Mol Cell       Date:  2002-02       Impact factor: 17.970

View more
  50 in total

1.  The ORF012 gene of Marek's disease virus type 1 produces a spliced transcript and encodes a novel nuclear phosphoprotein essential for virus growth.

Authors:  Timo Schippers; Keith Jarosinski; Nikolaus Osterrieder
Journal:  J Virol       Date:  2014-11-12       Impact factor: 5.103

2.  Comparative sequence analysis of a highly oncogenic but horizontal spread-defective clone of Marek's disease virus.

Authors:  Stephen J Spatz; Yuguang Zhao; Lawrence Petherbridge; Lorraine P Smith; Susan J Baigent; Venugopal Nair
Journal:  Virus Genes       Date:  2007-08-25       Impact factor: 2.332

3.  Revaccination with Marek's disease vaccines induces productive infection and superior immunity.

Authors:  Changxin Wu; Junji Gan; Qiao Jin; Chuangfu Chen; Ping Liang; Yantao Wu; Xuefen Liu; Li Ma; Fred Davison
Journal:  Clin Vaccine Immunol       Date:  2008-12-03

4.  Cytological and immunocytological detection and differentiation of Marek's disease and lymphoid leucosis in poultry.

Authors:  M Asok Kumar; M Palanivelu; R Barathidasan; Deepak Kumar; S D Singh; Shyma K Lateef; Rajendra Singh; K Dhama
Journal:  Virusdisease       Date:  2018-07-02

5.  Role of the short telomeric repeat region in Marek's disease virus replication, genomic integration, and lymphomagenesis.

Authors:  Annachiara Greco; Nadine Fester; Annemarie T Engel; Benedikt B Kaufer
Journal:  J Virol       Date:  2014-10-01       Impact factor: 5.103

6.  Molecular and pathogenicity characterization of Gallid herpesvirus 2 newly isolated in China from 2009 to 2013.

Authors:  Yan-Ping Zhang; Hong-Chao Lv; Ke-Yan Bao; Yu-Long Gao; Hong-Lei Gao; Xiao- le Qi; Hong-Yu Cui; Yong-Qiang Wang; Kai Li; Li Gao; Xiao-Mei Wang; Chang-Jun Liu
Journal:  Virus Genes       Date:  2015-11-26       Impact factor: 2.332

7.  Epigenetic repression of p16(INK4A) by latent Epstein-Barr virus requires the interaction of EBNA3A and EBNA3C with CtBP.

Authors:  Lenka Skalska; Robert E White; Melanie Franz; Michaela Ruhmann; Martin J Allday
Journal:  PLoS Pathog       Date:  2010-06-10       Impact factor: 6.823

8.  The Meq oncoprotein of Marek's disease virus interacts with p53 and inhibits its transcriptional and apoptotic activities.

Authors:  Xufang Deng; Xiangdong Li; Yang Shen; Yafeng Qiu; Zixue Shi; Donghua Shao; Yamei Jin; Hongjun Chen; Chan Ding; Li Li; Puyan Chen; Zhiyong Ma
Journal:  Virol J       Date:  2010-11-26       Impact factor: 4.099

9.  Homodimerization of the Meq viral oncoprotein is necessary for induction of T-cell lymphoma by Marek's disease virus.

Authors:  Andrew C Brown; Lorraine P Smith; Lydia Kgosana; Susan J Baigent; Venugopal Nair; Martin J Allday
Journal:  J Virol       Date:  2009-08-19       Impact factor: 5.103

10.  Deletion of 1.8-kb mRNA of Marek's disease virus decreases its replication ability but not oncogenicity.

Authors:  Aijun Sun; Yanpeng Li; Jingyan Wang; Shuai Su; Hongjun Chen; Hongfei Zhu; Jiabo Ding; Zhizhong Cui
Journal:  Virol J       Date:  2010-10-29       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.